{"success":true,"data":{"pressRelease":{"id":"160242","rtpr_id":"nGNX2yh2Fr-20261005","ticker":"BCRX","exchange":"NASDAQ","all_tickers":["BCRX"],"title":"BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth","author":"Globe Newswire","published_at":"2026-10-05T11:00:00.288Z","article_body":"—Supports BioCryst’s evolution toward a more disciplined R&D model\ncentered on external innovation—\n\nRESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst\nPharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a\nScientific Advisory Board (SAB) comprising seven accomplished scientific and\nindustry leaders with deep expertise across rare disease research and drug\ndevelopment. The SAB will provide independent scientific and strategic\nguidance as the Company advances its research and development strategy and\nbuilds a high value novel drug pipeline.\n\n“The formation of BioCryst’s Scientific Advisory Board marks an important\nstep in the evolution of our new R&D model,” said Dr. Sandeep Menon,\nBioCryst’s Chief Research and Development Officer. “External innovation is\nincreasingly central to how we build our pipeline, and guidance from leading\nscientists and physicians will sharpen our thinking and strengthen the\ndiligence behind each program we evaluate and advance. The Scientific Advisory\nBoard will work closely with me and our Chief Scientific Officer, Dr. David\nJenkins, as we shape and execute BioCryst’s R&D strategy.”\n\n“Building on our success in developing and commercializing medicines for\nhereditary angioedema, we are bringing the same rigor to the next generation\nof BioCryst medicines,” said Charlie Gayer, Chief Executive Officer. “With\nthe expertise of these highly experienced scientific advisors, BioCryst will\nbe better positioned to evaluate emerging opportunities and translate their\npotential into meaningful benefits for patients.”\n\nThe SAB will provide strategic guidance across BioCryst’s research and\ndevelopment activities, including pipeline expansion, external innovation\nopportunities, translational science and clinical development. The board will\nalso offer insights on regulatory strategy and help strengthen connections\nwith leading scientific, medical and patient communities worldwide.\n\n\"Few companies have demonstrated BioCryst’s ability to translate rigorous\nscience into rare disease medicines that reach patients, and that track record\nis what makes the Company’s evolution so compelling,\" said Dr. Anthony\nManning, Chair of the Scientific Advisory Board. \"The formation of this Board\nis an important step for BioCryst, and it is a privilege to chair a group with\nthis depth of experience across rare disease drug discovery, translational\nscience and clinical development. I am confident the Company’s decisions\nabout which science to pursue and how to advance it will benefit from the\ncollective judgment of its members.\"\n\nScientific Advisory Board Members:\n* Anthony (Tony) Manning, PhD, Chair, is Principal at Manning Bio Worldwide,\nLLC, advising biotechnology companies and academic institutions following a\n30-year career in pharmaceutical drug discovery and development. As Chief\nScientific Officer at Momenta Pharmaceuticals (now part of Johnson & Johnson),\nhe built a pipeline of first-in-class therapeutics for rare\nautoantibody-driven diseases, including nipocalimab (IMAAVY), now FDA-approved\nfor generalized myasthenia gravis and warm autoimmune hemolytic anemia, with\nadditional indications in development. Earlier, he led drug discovery efforts\nat Roche Pharmaceuticals and Biogen Idec, contributing to the approvals of\nActemra and Rituxan, and to the development of litifilimab, now in Phase 3 for\nlupus.\n \n* Dr. Christine Bulawa, PhD, received a PhD from the University of\nWisconsin-Madison and completed postdoctoral studies at Massachusetts\nInstitute of Technology (MIT). As part of her 20+ years in rare disease drug\ndiscovery, she was the first employee of FoldRx Pharmaceuticals and\ninstrumental in the preclinical development of tafamidis, the first\npharmacological treatment for transthyretin amyloidosis. As a senior leader in\nPfizer’s Rare Disease Research Unit, Dr. Bulawa built a pipeline of\ninnovative programs based on rigorously validated targets, spanning\nportfolio entry to clinical development, with a focus on small molecule and\ngenetic therapies to treat degenerative neurological, neuromuscular and\nprotein aggregation diseases. \n \n* Dr. Eric A. Hughes, MD, PhD, serves as Executive Vice President, Global\nResearch & Development and Chief Medical Officer at Teva Pharmaceuticals. A\nphysician-scientist who earned his MD and PhD from Yale University, Dr. Hughes\nbrings nearly 20 years of biopharmaceutical industry experience and is helping\nadvance Teva’s transformation into a leading innovative biopharmaceutical\ncompany, enabled by a world-class generics business.  Prior to Teva, he\nserved in leadership roles at Vertex, Novartis and Bristol Myers Squibb.\n \n* Dr. Stephanie Noviello, MD, MPH, is Chief Medical Officer at ILiAD\nBiotechnologies, Inc. She is a clinical development leader with extensive\nexperience across infectious diseases, virology, immunology, rare diseases and\nskeletal diseases at Novartis, Motif BioSciences, Bristol-Myers Squibb and\nSchering-Plough Research Institute.\n \n* Dr. Shashi Ramaiah, DVM, PhD, DACVP, DABT, is a board-certified Veterinary\nPathologist and Toxicologist who spent 18 years at Pfizer, most recently as\nVice President and Global Head of Discovery, Investigative and Translational\nSciences. He is Founder and CEO of SPECCRO, a drug development advisory firm\nthat helps biotechnology companies and investors de-risk programs and\nportfolios, drawing on more than 40 senior industry experts and extensive\nengagement with national and international scientific consortia.\n \n* Dr. Art Taveras, PhD, is a seasoned biopharmaceutical executive with over\n35 years of industry experience, specializing in leading R&D divisions across\nmajor public pharmaceutical corporations and biotech firms including Biogen\nIdec, Transform Therapeutics, X4 Pharmaceuticals, CoMET Therapeutics,\nShangPharma ChemPartner, Alantos Pharmaceuticals and Schering-Plough. His\nstrategic expertise as President, CEO, CSO and R&D Leader has advanced robust\npipelines and key global R&D partnerships, culminating in over 175 patent\napplication filings, 150 publications, 60 clinical trials, 6 regulatory agency\napprovals and 5 therapeutic platform technologies across commercial and\nclinical-stage assets for diseases in neurology, oncology, immunology,\nmetabolism and rare disease.\n \n* Dr. Ajay Yekkirala, PhD, is an experienced serial entrepreneur who\nco-founded Superluminal Medicines at RA Capital and built a strong investor\nsyndicate including NVIDIA, Eli Lilly, Insight Partners, Catalio, BVF and\nPerceptive Advisors. As Chief Scientific Officer, he directs the AI/ML\nplatform build and all pipeline R&D. Prior to Superluminal, Dr.\nYekkirala founded Blue Therapeutics to develop non-addictive painkillers. He\nreceived his PhD from the University of Minnesota and completed postdoctoral\ntraining at Harvard Medical School. He has authored several papers published\nin high-impact, peer-reviewed journals and advised various committees at the\nNIH, including EPPIC-NET at NINDS and Medication Development Research\nCommittee at NIDA.\nAbout BioCryst Pharmaceuticals\nBioCryst is a global biotechnology company focused on developing and\ncommercializing medicines for hereditary angioedema (HAE) and other rare\ndiseases, driven by its deep commitment to improving the lives of people\nliving with these conditions. BioCryst has commercialized ORLADEYO®\n(berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is\nadvancing a pipeline of potential first-in-class or best-in-class therapeutics\nfor rare diseases. For more information, please visit www.biocryst.com or\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=nNLgh-8pxJ_z23iuxGTcIgnmgyHtZItXlnpFm9mKZVFFxzoXRA4Q1DnGB65c0q7Z2CYXoXpoKUb9OGWN4rHEE-GJsnN8JeLwcBaAUJO-qlVr_hjpjliK5mUmEjMQBpvBFbpIkfAlzdcv9LUPLhuoJSyZ8v3qg5FxwpCPV-0_frTwl4b-FkanmccV6z4sl-q4knLyYQaPFiZ7_mlg-zutDeA2Wuww5MseLi_szCo8sNV7hkZpkt2ttFcrU9BPx8ZBL0L5NyDlcNNxAe62cd5WIeL3kinD-U3PksINAghw__mt2TcVgJ2dppPyARGyNqcioY9wvXqKo3MNWextmsiCSgq_5Lh_ndK9iCT_wA3UbOtaaHD-UBZ9sMReeCmKIsh3R2nmNjxaiPH1rXe41NFpCPDPzScD5jNNtS_h30ntyYOLjzCRtFPjNHk-H0wTLQZeoK3HcY2zFXO5AGBO2JQq-XmidfvZvw5kQ3cxEZrVxn9ytjPMcLelwhXh7T3mpxBSKjgTUoOd8-39vh3XMW4Jsq0_L8LNUOW1IAbBxwSY9GKPzUTsq28O2mAOHWfjhp6tTvLe7KYAFz6h_tOl5GsjPiN5c0z1WtaUwHqo39lDYr2Wk6vvKEE8fZ0qBlfamGNQ89lSabzDpWxPuHpqQ8jlbSasEEwLO3557bxKkNRh4V60R3pN-ojl6fCXoJ-C0NSL6OALgxJ-VyggQq_83ZMe8oPvuUbI-5iEF2WGfK5ypvFGa_ZgwJAL-amZp8Se5ozA).\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nregarding future results, performance, or achievements, expectations regarding\nBioCryst’s strategic shift to prioritize external innovation, expectations\nregarding pipeline development, the anticipated role and potential benefits of\nBioCryst’s Scientific Advisory Board, and statements related to BioCryst’s\nfuture operations, prospects and pipeline programs. These statements involve\nknown and unknown risks, uncertainties and other factors which may cause\nBioCryst’s actual results, performance, or achievements to be materially\ndifferent from any future results, performance, or achievements expressed or\nimplied by the forward-looking statements. These statements reflect our\ncurrent views with respect to future events and are based on assumptions and\nare subject to risks and uncertainties. Given these uncertainties, you should\nnot place undue reliance on these forward-looking statements. Some of the\nfactors that could affect the forward-looking statements contained herein\ninclude: BioCryst’s ability to successfully progress its pipeline\ndevelopment plans; guidance and recommendations provided by the Scientific\nAdvisory Board may not improve BioCryst’s evaluation or advancement of\npotential programs or result in the anticipated benefits; the commercial\nviability of BioCryst’s future rare disease therapies; ongoing and future\ndevelopment of product candidates may take longer than expected and may not\nhave positive results; product candidates, if approved, may not achieve market\nacceptance; the results of BioCryst’s partnerships with third parties may\nnot meet BioCryst’s current expectations; and BioCryst’s ability to\nrealize the contemplated benefits of its new R&D strategy and model and\nsuccessfully evaluate and execute external opportunities. This list is not\nexclusive. To see a more comprehensive list of risks, please refer to the\ndocuments BioCryst files periodically with the Securities and Exchange\nCommission, specifically BioCryst’s most recent Annual Report on Form 10-K,\nQuarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which\nidentify important factors that could cause actual results to differ\nmaterially from those contained in BioCryst’s projections and\nforward-looking statements.\n\nContact:\n\nInvestors:\ninvestorrelations@biocryst.com\n\nMedia:\nmedia@biocryst.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8b033909-1a3c-4811-b07b-fe03b12e00d2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2yh2Fr-20261005","title":"BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth","author":"Globe Newswire","ticker":"BCRX","created":"2026-10-05T11:00:00.288Z","tickers":["BCRX"],"exchange":"NASDAQ","article_body":"—Supports BioCryst’s evolution toward a more disciplined R&D model\ncentered on external innovation—\n\nRESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst\nPharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a\nScientific Advisory Board (SAB) comprising seven accomplished scientific and\nindustry leaders with deep expertise across rare disease research and drug\ndevelopment. The SAB will provide independent scientific and strategic\nguidance as the Company advances its research and development strategy and\nbuilds a high value novel drug pipeline.\n\n“The formation of BioCryst’s Scientific Advisory Board marks an important\nstep in the evolution of our new R&D model,” said Dr. Sandeep Menon,\nBioCryst’s Chief Research and Development Officer. “External innovation is\nincreasingly central to how we build our pipeline, and guidance from leading\nscientists and physicians will sharpen our thinking and strengthen the\ndiligence behind each program we evaluate and advance. The Scientific Advisory\nBoard will work closely with me and our Chief Scientific Officer, Dr. David\nJenkins, as we shape and execute BioCryst’s R&D strategy.”\n\n“Building on our success in developing and commercializing medicines for\nhereditary angioedema, we are bringing the same rigor to the next generation\nof BioCryst medicines,” said Charlie Gayer, Chief Executive Officer. “With\nthe expertise of these highly experienced scientific advisors, BioCryst will\nbe better positioned to evaluate emerging opportunities and translate their\npotential into meaningful benefits for patients.”\n\nThe SAB will provide strategic guidance across BioCryst’s research and\ndevelopment activities, including pipeline expansion, external innovation\nopportunities, translational science and clinical development. The board will\nalso offer insights on regulatory strategy and help strengthen connections\nwith leading scientific, medical and patient communities worldwide.\n\n\"Few companies have demonstrated BioCryst’s ability to translate rigorous\nscience into rare disease medicines that reach patients, and that track record\nis what makes the Company’s evolution so compelling,\" said Dr. Anthony\nManning, Chair of the Scientific Advisory Board. \"The formation of this Board\nis an important step for BioCryst, and it is a privilege to chair a group with\nthis depth of experience across rare disease drug discovery, translational\nscience and clinical development. I am confident the Company’s decisions\nabout which science to pursue and how to advance it will benefit from the\ncollective judgment of its members.\"\n\nScientific Advisory Board Members:\n* Anthony (Tony) Manning, PhD, Chair, is Principal at Manning Bio Worldwide,\nLLC, advising biotechnology companies and academic institutions following a\n30-year career in pharmaceutical drug discovery and development. As Chief\nScientific Officer at Momenta Pharmaceuticals (now part of Johnson & Johnson),\nhe built a pipeline of first-in-class therapeutics for rare\nautoantibody-driven diseases, including nipocalimab (IMAAVY), now FDA-approved\nfor generalized myasthenia gravis and warm autoimmune hemolytic anemia, with\nadditional indications in development. Earlier, he led drug discovery efforts\nat Roche Pharmaceuticals and Biogen Idec, contributing to the approvals of\nActemra and Rituxan, and to the development of litifilimab, now in Phase 3 for\nlupus.\n \n* Dr. Christine Bulawa, PhD, received a PhD from the University of\nWisconsin-Madison and completed postdoctoral studies at Massachusetts\nInstitute of Technology (MIT). As part of her 20+ years in rare disease drug\ndiscovery, she was the first employee of FoldRx Pharmaceuticals and\ninstrumental in the preclinical development of tafamidis, the first\npharmacological treatment for transthyretin amyloidosis. As a senior leader in\nPfizer’s Rare Disease Research Unit, Dr. Bulawa built a pipeline of\ninnovative programs based on rigorously validated targets, spanning\nportfolio entry to clinical development, with a focus on small molecule and\ngenetic therapies to treat degenerative neurological, neuromuscular and\nprotein aggregation diseases. \n \n* Dr. Eric A. Hughes, MD, PhD, serves as Executive Vice President, Global\nResearch & Development and Chief Medical Officer at Teva Pharmaceuticals. A\nphysician-scientist who earned his MD and PhD from Yale University, Dr. Hughes\nbrings nearly 20 years of biopharmaceutical industry experience and is helping\nadvance Teva’s transformation into a leading innovative biopharmaceutical\ncompany, enabled by a world-class generics business.  Prior to Teva, he\nserved in leadership roles at Vertex, Novartis and Bristol Myers Squibb.\n \n* Dr. Stephanie Noviello, MD, MPH, is Chief Medical Officer at ILiAD\nBiotechnologies, Inc. She is a clinical development leader with extensive\nexperience across infectious diseases, virology, immunology, rare diseases and\nskeletal diseases at Novartis, Motif BioSciences, Bristol-Myers Squibb and\nSchering-Plough Research Institute.\n \n* Dr. Shashi Ramaiah, DVM, PhD, DACVP, DABT, is a board-certified Veterinary\nPathologist and Toxicologist who spent 18 years at Pfizer, most recently as\nVice President and Global Head of Discovery, Investigative and Translational\nSciences. He is Founder and CEO of SPECCRO, a drug development advisory firm\nthat helps biotechnology companies and investors de-risk programs and\nportfolios, drawing on more than 40 senior industry experts and extensive\nengagement with national and international scientific consortia.\n \n* Dr. Art Taveras, PhD, is a seasoned biopharmaceutical executive with over\n35 years of industry experience, specializing in leading R&D divisions across\nmajor public pharmaceutical corporations and biotech firms including Biogen\nIdec, Transform Therapeutics, X4 Pharmaceuticals, CoMET Therapeutics,\nShangPharma ChemPartner, Alantos Pharmaceuticals and Schering-Plough. His\nstrategic expertise as President, CEO, CSO and R&D Leader has advanced robust\npipelines and key global R&D partnerships, culminating in over 175 patent\napplication filings, 150 publications, 60 clinical trials, 6 regulatory agency\napprovals and 5 therapeutic platform technologies across commercial and\nclinical-stage assets for diseases in neurology, oncology, immunology,\nmetabolism and rare disease.\n \n* Dr. Ajay Yekkirala, PhD, is an experienced serial entrepreneur who\nco-founded Superluminal Medicines at RA Capital and built a strong investor\nsyndicate including NVIDIA, Eli Lilly, Insight Partners, Catalio, BVF and\nPerceptive Advisors. As Chief Scientific Officer, he directs the AI/ML\nplatform build and all pipeline R&D. Prior to Superluminal, Dr.\nYekkirala founded Blue Therapeutics to develop non-addictive painkillers. He\nreceived his PhD from the University of Minnesota and completed postdoctoral\ntraining at Harvard Medical School. He has authored several papers published\nin high-impact, peer-reviewed journals and advised various committees at the\nNIH, including EPPIC-NET at NINDS and Medication Development Research\nCommittee at NIDA.\nAbout BioCryst Pharmaceuticals\nBioCryst is a global biotechnology company focused on developing and\ncommercializing medicines for hereditary angioedema (HAE) and other rare\ndiseases, driven by its deep commitment to improving the lives of people\nliving with these conditions. BioCryst has commercialized ORLADEYO®\n(berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is\nadvancing a pipeline of potential first-in-class or best-in-class therapeutics\nfor rare diseases. For more information, please visit www.biocryst.com or\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=nNLgh-8pxJ_z23iuxGTcIgnmgyHtZItXlnpFm9mKZVFFxzoXRA4Q1DnGB65c0q7Z2CYXoXpoKUb9OGWN4rHEE-GJsnN8JeLwcBaAUJO-qlVr_hjpjliK5mUmEjMQBpvBFbpIkfAlzdcv9LUPLhuoJSyZ8v3qg5FxwpCPV-0_frTwl4b-FkanmccV6z4sl-q4knLyYQaPFiZ7_mlg-zutDeA2Wuww5MseLi_szCo8sNV7hkZpkt2ttFcrU9BPx8ZBL0L5NyDlcNNxAe62cd5WIeL3kinD-U3PksINAghw__mt2TcVgJ2dppPyARGyNqcioY9wvXqKo3MNWextmsiCSgq_5Lh_ndK9iCT_wA3UbOtaaHD-UBZ9sMReeCmKIsh3R2nmNjxaiPH1rXe41NFpCPDPzScD5jNNtS_h30ntyYOLjzCRtFPjNHk-H0wTLQZeoK3HcY2zFXO5AGBO2JQq-XmidfvZvw5kQ3cxEZrVxn9ytjPMcLelwhXh7T3mpxBSKjgTUoOd8-39vh3XMW4Jsq0_L8LNUOW1IAbBxwSY9GKPzUTsq28O2mAOHWfjhp6tTvLe7KYAFz6h_tOl5GsjPiN5c0z1WtaUwHqo39lDYr2Wk6vvKEE8fZ0qBlfamGNQ89lSabzDpWxPuHpqQ8jlbSasEEwLO3557bxKkNRh4V60R3pN-ojl6fCXoJ-C0NSL6OALgxJ-VyggQq_83ZMe8oPvuUbI-5iEF2WGfK5ypvFGa_ZgwJAL-amZp8Se5ozA).\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nregarding future results, performance, or achievements, expectations regarding\nBioCryst’s strategic shift to prioritize external innovation, expectations\nregarding pipeline development, the anticipated role and potential benefits of\nBioCryst’s Scientific Advisory Board, and statements related to BioCryst’s\nfuture operations, prospects and pipeline programs. These statements involve\nknown and unknown risks, uncertainties and other factors which may cause\nBioCryst’s actual results, performance, or achievements to be materially\ndifferent from any future results, performance, or achievements expressed or\nimplied by the forward-looking statements. These statements reflect our\ncurrent views with respect to future events and are based on assumptions and\nare subject to risks and uncertainties. Given these uncertainties, you should\nnot place undue reliance on these forward-looking statements. Some of the\nfactors that could affect the forward-looking statements contained herein\ninclude: BioCryst’s ability to successfully progress its pipeline\ndevelopment plans; guidance and recommendations provided by the Scientific\nAdvisory Board may not improve BioCryst’s evaluation or advancement of\npotential programs or result in the anticipated benefits; the commercial\nviability of BioCryst’s future rare disease therapies; ongoing and future\ndevelopment of product candidates may take longer than expected and may not\nhave positive results; product candidates, if approved, may not achieve market\nacceptance; the results of BioCryst’s partnerships with third parties may\nnot meet BioCryst’s current expectations; and BioCryst’s ability to\nrealize the contemplated benefits of its new R&D strategy and model and\nsuccessfully evaluate and execute external opportunities. This list is not\nexclusive. To see a more comprehensive list of risks, please refer to the\ndocuments BioCryst files periodically with the Securities and Exchange\nCommission, specifically BioCryst’s most recent Annual Report on Form 10-K,\nQuarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which\nidentify important factors that could cause actual results to differ\nmaterially from those contained in BioCryst’s projections and\nforward-looking statements.\n\nContact:\n\nInvestors:\ninvestorrelations@biocryst.com\n\nMedia:\nmedia@biocryst.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8b033909-1a3c-4811-b07b-fe03b12e00d2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-05T11:00:00.548538865Z","server_sent_at_ms":1791198000548},"received_at":"2026-10-05T11:00:00.608Z","source_url":null},"analysis":{"id":"148817","press_release_id":"160242","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"BioCryst formed a seven-member Scientific Advisory Board of rare disease drug development experts to guide its R&D strategy and pipeline building.\n\nThe move supports the company's stated evolution toward a more disciplined R&D model centered on external innovation, advising on pipeline expansion, translational science, clinical development and regulatory strategy.\n\nThe announcement contains no financial figures or new program data; its impact is indirect, signaling an increased emphasis on in-licensing and external opportunities.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"SAB formation signals BioCryst leaning further into external innovation and BD for pipeline expansion -- watch for subsequent licensing deals."},"keyFigures":{},"quotedText":"External innovation is increasingly central to how we build our pipeline, and guidance from leading scientists and physicians will sharpen our thinking and strengthen the diligence behind each program we evaluate and advance.","namedEntities":{"people":[{"name":"Dr. Sandeep Menon","role":"Chief Research and Development Officer"},{"name":"Dr. David Jenkins","role":"Chief Scientific Officer"},{"name":"Charlie Gayer","role":"CEO"},{"name":"Dr. Anthony Manning","role":"Chair, Scientific Advisory Board"},{"name":"Dr. Christine Bulawa","role":"SAB member"},{"name":"Dr. Eric A. Hughes","role":"SAB member; CMO of Teva Pharmaceuticals"},{"name":"Dr. Stephanie Noviello","role":"SAB member"},{"name":"Dr. Shashi Ramaiah","role":"SAB member"},{"name":"Dr. Art Taveras","role":"SAB member"},{"name":"Dr. Ajay Yekkirala","role":"SAB member"}],"products":["ORLADEYO (berotralstat)","nipocalimab (IMAAVY)","tafamidis","Actemra","Rituxan","litifilimab"],"companies":[{"name":"BioCryst Pharmaceuticals, Inc.","ticker":"BCRX","relationship":"filer"},{"name":"Teva Pharmaceuticals","relationship":"SAB member employer"},{"name":"Pfizer","relationship":"SAB members' prior employer"},{"name":"Superluminal Medicines","relationship":"SAB member co-founded company"},{"name":"ILiAD Biotechnologies, Inc.","relationship":"SAB member employer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Formation of an external Scientific Advisory Board is a governance/advisory update with no financial figures, program data, or near-term revenue implications. Boilerplate strategic-signaling announcement."},"tickerRelevance":{"others":[],"primary":"BCRX"},"globalImportance":12,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"advisory-board formation, no financial or clinical data","sectorWeight":"biotech governance events score low absent program catalysts","issuerAuthored":true}},"event_type":"board_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"BioCryst formed a seven-member Scientific Advisory Board of rare disease drug development experts to guide its R&D strategy and pipeline building.\n\nThe move supports the company's stated evolution toward a more disciplined R&D model centered on external innovation, advising on pipeline expansion, translational science, clinical development and regulatory strategy.\n\nThe announcement contains no financial figures or new program data; its impact is indirect, signaling an increased emphasis on in-licensing and external opportunities.","key_figures":{},"named_entities":{"people":[{"name":"Dr. Sandeep Menon","role":"Chief Research and Development Officer"},{"name":"Dr. David Jenkins","role":"Chief Scientific Officer"},{"name":"Charlie Gayer","role":"CEO"},{"name":"Dr. Anthony Manning","role":"Chair, Scientific Advisory Board"},{"name":"Dr. Christine Bulawa","role":"SAB member"},{"name":"Dr. Eric A. Hughes","role":"SAB member; CMO of Teva Pharmaceuticals"},{"name":"Dr. Stephanie Noviello","role":"SAB member"},{"name":"Dr. Shashi Ramaiah","role":"SAB member"},{"name":"Dr. Art Taveras","role":"SAB member"},{"name":"Dr. Ajay Yekkirala","role":"SAB member"}],"products":["ORLADEYO (berotralstat)","nipocalimab (IMAAVY)","tafamidis","Actemra","Rituxan","litifilimab"],"companies":[{"name":"BioCryst Pharmaceuticals, Inc.","ticker":"BCRX","relationship":"filer"},{"name":"Teva Pharmaceuticals","relationship":"SAB member employer"},{"name":"Pfizer","relationship":"SAB members' prior employer"},{"name":"Superluminal Medicines","relationship":"SAB member co-founded company"},{"name":"ILiAD Biotechnologies, Inc.","relationship":"SAB member employer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T11:00:07.517Z","global_importance":12,"audience_relevance":18,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"advisory-board formation, no financial or clinical data","sectorWeight":"biotech governance events score low absent program catalysts","issuerAuthored":true}},"durationMs":6878,"modelName":"glm-5.3-flashx"}}